Stay up-to-date with the latest news from research, product development and clinical studies
The GHSG HD21 substudy published in Blood demonstrates that LymphoVista detects ctDNA-MRD after just two cycles of chemotherapy, identifying patients at 5.3-fold higher risk of relapse and clarifying 70% of false-positive PET results.
The IMvigor011 trial is the first randomised Phase III study to prove that ctDNA-MRD testing can guide adjuvant immunotherapy decisions in muscle-invasive bladder cancer, with a 36% reduction in disease recurrence risk and 97.1% survival in MRD-negative patients who received no treatment.
LIQOMICS introduces liquidbiopsyinfo.com, a structured, evidence-based resource for liquid biopsy applications. Plus, our latest study on ctDNA-MRD in Hodgkin lymphoma is now published in Blood.
With the latest NCCN Guidelines, ctDNA-MRD testing has been officially recommended for DLBCL patients. Discover how this liquid biopsy innovation is reducing unnecessary biopsies and clarifying PET-positive findings.
Solid tumors are abnormal tissue masses that develop in organs due to uncontrolled cell growth. Traditional biopsies have limitations, driving the development of minimally invasive liquid biopsies. This article explores current data on liquid biopsy-based MRD assessment in colorectal cancer, breast cancer, and lung cancer.
In recent years, researchers have realized that circulating cell-free DNA (cfDNA) in the blood carries far more information than just mutations. cfDNA fragments reflect the way chromatin is packaged and cut during apoptosis.
Lymphoma is a type of cancer that originates from lymphocytes, which are white blood cells that help fight infections as part of the immune response. There are two main types of lymphoma: Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL).
Assessment of minimal residual disease (MRD) is becoming an increasingly important tool for early detection of tumor recurrence and guiding treatment decisions in the management of solid tumors.
Minimal residual disease (MRD) refers to a small number of cancer cells that can remain in a patient’s body after treatment, potentially leading to relapse.
In May, we kicked off our latest research project, “Fragmentomics by LIQOMICS”, supported with approx. €370,000 in funding from the state of North Rhine-Westphalia.
In our last article, we explored the importance of minimal residual disease (MRD) in cancer treatment and highlighted its role in predicting relapse and guiding personalized therapy.
Solid tumors are abnormal masses of tissue that develop when cells grow uncontrollably and do not contain cysts or liquid areas (NIH, national cancer institute). They can be benign (non-cancerous) or malignant (cancerous). Common types of solid tumors include carcinomas, sarcomas, and lymphomas. Solid tumors can occur in various parts of the body, such as the breast, lung, prostate, colon, and skin.
In cancer treatment, early and accurate diagnosis is only part of the challenge. Equally important is ensuring that a patient remains cancer-free after initial therapy, since cancer has a tendency to return if any malignant cells remain.
We are thrilled to announce that our project, Fragmentomics by LIQOMICS, has been selected as one of only 4 projects that will be supported as part of the prestigious funding program ZukunftBIO.NRW.
In our last article, we introduced the basics of circulating cell-free DNA (cfDNA), its release and clearance mechanisms, and its central role in cancer diagnostics. Now that you are familiar with the fundamental concepts of cfDNA, this follow-up dives deeper into its biological significance.
LIQOMICS, a leading innovator in cancer diagnostics, is thrilled to announce the presentation of data on the LymphoVista HL assay at the 2024 Annual Meeting of the American Society of Hematology (ASH) in San Diego.
Recent advances in cancer research have significantly expanded our understanding of the complex biology of tumors. Particularly promising is the study of circulating tumor DNA (ctDNA), tiny, cell-free DNA fragments released into the bloodstream by cancer cells.
We’re thrilled that next week, from October 26-28, 2024, the highly anticipated 13th International Symposium on Hodgkin Lymphoma (ISHL 13) will take place in Cologne.
The analysis of minimal residual disease (MRD) using circulating tumor DNA (ctDNA) is gaining increasing importance as a precise tool for monitoring cancer during and after treatment. But what do MRD values actually mean – and how can they be translated into something more tangible?
We are always on the lookout for collaborators.